Baxter International (BAX)
(Delayed Data from NYSE)
$35.87 USD
+0.17 (0.48%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $35.75 -0.12 (-0.33%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$35.87 USD
+0.17 (0.48%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $35.75 -0.12 (-0.33%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum C VGM
Zacks News
Earnings Preview: Baxter International (BAX) Q4 Earnings Expected to Decline
by Zacks Equity Research
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Baxter (BAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) fourth-quarter results are likely to reflect growth in elective surgical procedures, offset by currency and supply challenges. Hillrom's products are likely to have boosted sales.
Company News for Jan 10, 2023
by Zacks Equity Research
Companies In The News Are: REGN, LULU, DCT, BAX.
Baxter (BAX) Plans to Form Standalone Kidney Care Company
by Zacks Equity Research
Baxter (BAX) plans several strategic actions, including spin-off of Renal Care and Acute Therapies global business units into an independent, publicly traded company to simplify its operating model.
Is the Options Market Predicting a Spike in Baxter International (BAX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Baxter International (BAX) stock based on the movements in the options market lately.
Baxter (BAX) Q3 Earnings Meet Estimates, Hilrom Adds $735 M
by Zacks Equity Research
Baxter's (BAX) third-quarter results reflect the robust performance of the Medication Delivery business unit and Hilrom's businesses.
Baxter International (BAX) Q3 Earnings Match Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of 0% and 0.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Q3 Earnings on Oct 27: LH, BIO & More
by Indrajit Bandyopadhyay
Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how LH, BIO, BAX, DXCM and WST are likely to fare this time.
MacroGenics (MGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
MacroGenics (MGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for West Pharmaceutical (WST) in Q3 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements are likely to hurt the top and bottom lines.
Stryker (SYK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) third-quarter results are likely to reflect strong segmental performances.
Is a Beat Likely for DexCom (DXCM) This Earnings Season?
by Zacks Equity Research
DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.
Baxter (BAX) to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Baxter's (BAX) third-quarter results are likely to reflect growth in its Medication Delivery and Advanced Surgery businesses. Hillrom's products are likely to have boosted sales.
Analysts Estimate Baxter International (BAX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Reasons to Retain Baxter (BAX) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Baxter (BAX) due to its strong product portfolio.
Neogen (NEOG) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -6.25% and 2.51%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?
Baxter (BAX) Novum IQ SYR's FDA Clearance Boosts Patient Care
by Zacks Equity Research
Latest regulatory approval for Baxter's (BAX) Novum IQ SYR is expected to provide safe and accurate infusions for vulnerable patients.
Baxter (BAX) Q2 Earnings Miss Estimates, Hilrom Adds $715 M
by Zacks Equity Research
Baxter's (BAX) second-quarter results reflect the robust performance of the Medication Delivery business unit and Hilrom's businesses.
Baxter International (BAX) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of -1.14% and 3.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Stryker (SYK) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of -0.88% and 0.78%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Baxter (BAX) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) second-quarter results are likely to reflect growth in its Medication Delivery and BioPharma Solutions businesses. Hillrom's products are likely to have boosted sales
3 Reasons to Retain Baxter (BAX) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Baxter (BAX) due to its strong product portfolio.
Should iShares Morningstar MidCap ETF (IMCB) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IMCB
Here's Why You Should Retain Baxter (BAX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio and regulatory clearances.
Quidel (QDEL) Down 9.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Quidel (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.